Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 25, 2023 16:01 ET | Source: Genelux Corporation

Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) Oncology

Phase 2 Trial of Olvi-Vec-primed immunochemotherapy in heavily pre-treated patients Met primary endpoint of objective response rate with deep and durable responsesGenerated promising...